Literature DB >> 7046329

Glucuronidation of morphine in human liver and interaction with oxazepam.

J Säwe, G M Pacifici, L Kager, C von Bahr, A Rane.   

Abstract

Morphine is primarily metabolized through glucuronidation by a microsomal UDP-glucuronyltransferase. With the use of 14C-morphine the activity of this enzyme was measured in hepatic microsomes from ten kidney transplant donors with total cerebral infarction and four icteric patients with pancreatic carcinoma. In the former livers the rate of glucuronidation varied from 1.08 to 8.67 nmol per mg microsomal protein per min, with a mean value of 3.83. These values were somewhat higher than in the liver biopsies from the four cancer patients. Oxazepam, at 1/10 the concentration of morphine, inhibited the morphine glucuronidation by 35%. The inhibition was competitive. Salicylamide also inhibited the morphine glucuronidation but only at concentrations considerably higher than morphine. The relevance of the in vitro data for the in vivo situation is unclear, since the concentrations employed in this study are several-fold higher than those encountered in the plasma of patients treated with these drugs.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7046329     DOI: 10.1111/j.1399-6576.1982.tb01845.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand Suppl        ISSN: 0515-2720


  6 in total

1.  Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin.

Authors:  L O Eriksson; E Wåhlin-Boll; H Liedholm; P Seideman; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Metabolism of narcotics.

Authors:  H McQuay; A Moore
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-21

3.  Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation.

Authors:  J Säwe; L Kager; J O Svensson Eng; A Rane
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

Review 4.  High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.

Authors:  J Säwe
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

5.  In vitro forecasting of drugs that may interfere with codeine bioactivation.

Authors:  P Dayer; J Desmeules; R Striberni
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Apr-Jun       Impact factor: 2.441

6.  Morphine glucuronidation in human fetal and adult liver.

Authors:  G M Pacifici; J Säwe; L Kager; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.